Taizhou Hospital
73
20
21
13
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
1.4%
1 terminated/withdrawn out of 73 trials
92.9%
+6.4% vs industry average
16%
12 trials in Phase 3/4
8%
1 of 13 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (73)
Exploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG)
Role: collaborator
Enhancing Critical Thinking Competency and Nursing Quality in Critically Ill Patient Care
Role: lead
Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen
Role: collaborator
Fertility Outcomes In Young Breast Cancer Patients And Their Prognosis And Offspring Health
Role: lead
Tumor Control, Treatment Toxicity, Quality of Life and Bio-Imaging Repository Databank (TQ-BIRD) for Cancer Patients
Role: collaborator
Efficacy and Safety of TJ0113 Capsule in Patients With Parkinson's Disease
Role: collaborator
SCRT Combined With Chemotherapy and Iparomlimab and Tuvonralimab in MSS or pMMR Patients With Locally Advanced Rectal Cancer
Role: collaborator
Eliminating Breast Surgery for Breast Cancer Patients With Clinical Complete Response to Neoadjuvant Systemic Therapy
Role: collaborator
Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma
Role: collaborator
Mindfulness-Based Intervention Targeting Psychological Capital to Reduce Job Burnout Among Nurses
Role: lead
The National Registry Study For the Real-world Patients With Parkinsonian Disorders in China
Role: collaborator
Butylphthalide for Cognitive Impairment in Elderly Patients With Focal Epilepsy
Role: collaborator
Risankizumab for Fibrostenotic Crohn's Disease Treatment
Role: collaborator
Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
Role: collaborator
Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma
Role: collaborator
Comparison of Sequential to Initial Combination Therapy in PAH
Role: collaborator
Early Antiplatelet Therapy After Hemorrhagic Infarction in Acute Ischemic Stroke Treated With Intravenous Thrombolysis (HITs)
Role: collaborator
Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma
Role: collaborator
Establishment and Clinical Application of Breast Cancer Risk Prediction Model Based on Traditional Chinese Medicine Four Diagnostic Instruments and Ultrasound
Role: lead
Phase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLC
Role: collaborator